Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 3-SEP-2021.

09/03/2021 EST

610,329,800 Ordinary Shares of SciClone Pharmaceuticals (Holdings) Limited are subject to a Lock-Up Agreement Ending on 3-SEP-2021. These Ordinary Shares will be under lockup for 186 days starting from 1-MAR-2021 to 3-SEP-2021. Details: Each of Avengers Limited, Ascendent Silver (Cayman) Limited, Ocean Falcon Limited, Boying Investments Limited, Convergence International Holdings Ltd. and Corto Co., Ltd. (the “Undersigned Shareholders”) has agreed to enter into a lock-up undertaking deed in favor of the Joint Sponsors and the Joint Representatives. Pursuant to the Lock-up Undertaking Deeds, each of the Undersigned Shareholders agrees that, it will not, from the date of the respective Lock-up Undertaking Deed and ending on, and including, the date that is six months after the Listing Date (the “Six-Month Period”), dispose of any Relevant Shares or any interest in any company or entity holding or controlling (directly or indirectly) any Relevant Shares or, permit or cause a change in control of any company or entity holding or controlling (directly or indirectly) any Relevant Shares. GL Capital Group, single largest Shareholder, has undertaken to the Hong Kong Stock Exchange that, it shall not, unless in compliance with the requirements of the Listing Rules, in the period commencing on the date by reference to which disclosure of its shareholding is made in this prospectus and ending on the date which is six months from the Listing Date (the “First SixMonth Period”), dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares in respect of which it is shown by this prospectus to be the beneficial owner. The shares held by the cornerstone investors to be held under lock up until September 03, 2021.


© S&P Capital IQ 2021
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
2021SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
2021SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
2021NMPA Grants Priority Review to BLA of DANYELZA®
CI
2021610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
2021Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for..
CI
2021ThinkGeek Network Technology Files for Hong Kong IPO
MT
2021Beijing Evercare Medical Files for Hong Kong IPO
MT
More news
Financials
Sales 2021 2 437 M 384 M 384 M
Net income 2021 891 M 141 M 141 M
Net cash 2021 719 M 113 M 113 M
P/E ratio 2021 5,28x
Yield 2021 5,48%
Capitalization 4 723 M 745 M 745 M
EV / Sales 2021 1,64x
EV / Sales 2022 1,21x
Nbr of Employees 850
Free-Float -
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,00 CNY
Average target price 13,38 CNY
Spread / Average Target 91,1%
EPS Revisions
Managers and Directors
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors